Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma

<p>Eluted tumor-associated antigen-derived peptides.</p>

Сохранить в:

Библиографические подробности
Главный автор:	Jitske van den Bulk (17142147) (author)
Другие авторы:	Els M.E. Verdegaal (17142150) (author), Manon van der Ploeg (17142153) (author), Marten Visser (17142156) (author), Joana B. Nunes (17142159) (author), Arnoud H. de Ru (17142162) (author), Rayman T.N. Tjokrodirijo (17142165) (author), Marieke E. Ijsselsteijn (17142168) (author), Natasja I. Janssen (17142171) (author), Ruud van der Breggen (17142174) (author), Linda de Bruin (17142177) (author), Pita de Kok (17142180) (author), George M.C. Janssen (17142183) (author), Dina Ruano (17142186) (author), Ellen H.W. Kapiteijn (17142189) (author), Peter A. van Veelen (17142192) (author), Noel F.C.C. de Miranda (17142195) (author), Sjoerd H. van der Burg (15021483) (author)
Опубликовано:	2025
Предметы:	Cancer Immuno-oncology Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy Skin Cancers Melanoma
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!

Схожие документы

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
по: Jitske van den Bulk (17142147)
Опубликовано: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
по: Jitske van den Bulk (17142147)
Опубликовано: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
по: Jitske van den Bulk (17142147)
Опубликовано: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
по: Jitske van den Bulk (17142147)
Опубликовано: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
по: Michael Kilian (16697663)
Опубликовано: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
по: Michael Kilian (16697663)
Опубликовано: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
по: Michael Kilian (16697663)
Опубликовано: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
по: Maria Lozano-Rabella (15056515)
Опубликовано: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
по: Maria Lozano-Rabella (15056515)
Опубликовано: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
по: Maria Lozano-Rabella (15056515)
Опубликовано: (2025)

Supplementary Table 1 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
по: Caroline Robert (15032672)
Опубликовано: (2025)

Supplementary Table 2 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
по: Caroline Robert (15032672)
Опубликовано: (2025)

Supplementary Table 3 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
по: Caroline Robert (15032672)
Опубликовано: (2025)

Supplementary Table 4 from Phase I Study of Androgen Deprivation Therapy in Combination with Anti–PD-1 in Melanoma Patients Pretreated with Anti–PD-1
по: Caroline Robert (15032672)
Опубликовано: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
по: Hansol Lee (15054787)
Опубликовано: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
по: Hansol Lee (15054787)
Опубликовано: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
по: Hansol Lee (15054787)
Опубликовано: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
по: Hansol Lee (15054787)
Опубликовано: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
по: Joseph Toker (15399882)
Опубликовано: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
по: Joseph Toker (15399882)
Опубликовано: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
по: Joseph Toker (15399882)
Опубликовано: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
по: Joseph Toker (15399882)
Опубликовано: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
по: Joseph Toker (15399882)
Опубликовано: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
по: Joseph Toker (15399882)
Опубликовано: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
по: Joseph Toker (15399882)
Опубликовано: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
по: Ankita Mitra (17141783)
Опубликовано: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
по: Ankita Mitra (17141783)
Опубликовано: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
по: Ankita Mitra (17141783)
Опубликовано: (2025)

Supplementary Table S5 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
по: Christine Pich-Bavastro (16509238)
Опубликовано: (2025)

Supplementary Figure 5 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
по: Wei Liu (20030)
Опубликовано: (2025)

Supplementary Table S1 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
по: Christine Pich-Bavastro (16509238)
Опубликовано: (2025)

Supplementary Table S2 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
по: Christine Pich-Bavastro (16509238)
Опубликовано: (2025)

Supplementary Table S3 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
по: Christine Pich-Bavastro (16509238)
Опубликовано: (2025)

Supplementary Table S4 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
по: Christine Pich-Bavastro (16509238)
Опубликовано: (2025)

Supplementary Table S6 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
по: Christine Pich-Bavastro (16509238)
Опубликовано: (2025)

Supplementary Table S7 from Activin A–Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer
по: Christine Pich-Bavastro (16509238)
Опубликовано: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
по: Rohit Thummalapalli (17314483)
Опубликовано: (2025)

Supplementary Figure 1 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
по: Wei Liu (20030)
Опубликовано: (2025)

Supplementary Figure 2 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
по: Wei Liu (20030)
Опубликовано: (2025)

Supplementary Figure 3 from BAFF Attenuates Immunosuppressive Monocytes in the Melanoma Tumor Microenvironment
по: Wei Liu (20030)
Опубликовано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_blvokujftr4ptq27te88a3jv8k